AstraZeneca aims to review bone cancer care with new data across the treatment diapason at SABCS 2022
AstraZeneca will present new data advancing its ambition to review care at the 2022 San Antonio bone Cancer Symposium( SABCS), 6- 10 December 2022.
Twelve AstraZeneca drugs and implicit new drugs will be featured in 55 donations, including five oral donations, showcasing the Company’s growing leadership across different subtypes and stages of bone cancer.
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said “ Our data at SABCS are strong confirmation of our clinical strategy to give coming- generation treatment results for cases with nearly all major types of bone cancer. We’re agitated to partake results from the vital CAPItello- 291 trial, which will support the occasion of our new AKT asset capivasertib for cases with HR-positive complaint. We also look forward to presenting defining data from the SERENA- 2 Phase II trial that will demonstrate the eventuality of our coming- generation SERD camizestrant to ameliorate upon presently available endocrine curatives for cases with ER- driven complaint. ”
Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said “ As we close another time of improvements in bone cancer, our presence at SABCS will showcase the occasion for our portfolio to shape clinical practice and review care across subtypes and stages of this complaint. Compelling results for implicit new drugs capivasertib and camizestrant as well as new data from antibody medicine conjugates Enhertu and datopotamab deruxtecan will emphasize our focus on addressing the topmost unmet requirements and delivering personalised treatment for further cases with bone cancer. ”
Aiming to set new norms of care across HER2-positive metastatic bone cancer
Two late- breaking donations from the fortune- bone clinical programme will punctuate the efficacity of Enhertu( trastuzumab deruxtecan) treatment in cases with HER2-positive metastatic bone cancer across lines of remedy.
streamlined results from the fortune- Breast03 Phase III trial of Enhertu versus trastuzumab emtansine( T- DM1) in cases with HER2-positive bone cancer preliminarily treated with trastuzumab and a taxane will be presented, including streamlined progression-free survival( PFS) data and overall survival( zilches) results.
In addition, primary results from the fortune- Breast02 Phase III trial will be presented, further demonstrating the clinical benefit of Enhertu compared to conventional chemotherapy- grounded rules in cases with HER2-positive metastatic bone cancer preliminarily treated with T- DM1.
Data will also be presented from the ROSET- BM retrospective study and DEBBRAH Phase II trial further attesting Enhertu exertion in cases with HER2-positive or HER2-low metastatic bone cancer with active or stable brain metastases.
Reshaping treatment prospects in HR-positive advanced bone cancer
A late- breaking donation will illustrate the Company’s focus on addressing endocrine resistance in advanced HR-positive bone cancer.
Detailed data will be participated from the CAPItello- 291 Phase III trial of the AKT asset capivasertib in combination with Faslodex( fulvestrant) versus Faslodex alone in endocrine- resistant, HR-positive, HER2-low or negative advanced bone cancer. CAPItello- 291 lately met both primary endpoints, demonstrating enhancement in PFS in the overall patient population and in a prespecified biomarker group of cases whose tumours had qualifying differences in the PIK3CA, AKT1 or PTEN genes.
Several donations will establish the clinical eventuality of the coming- generation oral picky oestrogen receptor inveigler( SERD) camizestrant as a monotherapy or in combination for cases with oestrogen receptor positive( ER-positive) advanced bone cancer.
A late- breaking donation will punctuate detailed results from the positive SERENA- 2 Phase II trial of camizestrant versus Faslodex in advanced ER-positive bone cancer.
Analyses from farther cohorts of the SERENA- 1 Phase I trial of advanced ER-positive bone cancer will also be presented, which will show the eventuality to combine camizestrant with abemaciclib, a CDK4/ 6 asset.
A limelight bill will feature data showing promising preclinical exertion with camizestrant in ER-positive bone cancer when used in double and triadic combinations with CDK4/ 6, mTOR, AKT or PI3K impediments, in ESR1 wild- type and shifted models.
also, several donations will showcase AstraZeneca’s commitment to transubstantiating the treatment geography for HR-positive bone cancer with antibody medicine conjugates( ADCs) and by relating new tumour subtypes that may respond to targeted curatives.
A bill donation of results from the TROPION- PanTumor01 Phase I trial will characterise the safety and encouraging clinical exertion of datopotamab deruxtecan in cases with heavilypre-treated HR-positive, HER2-negative inoperable or metastatic bone cancer. Datopotamab deruxtecan is also being tested in these cases in earlier lines of treatment in the randomised TROPION- Breast01 Phase III trial.
Multiple bill donations will partake results for implicit individual tools to more identify and optimise treatment for cases across the diapason of HER2 expression, including those with HER2-low tumours who may profit from treatment with Enhertu.
Data from colorful group analyses from the fortune- Breast04 Phase III trial will support the clinical meaningfulness of HER2-low as an practicable case member in cases with metastatic bone cancer.
Reconsidering care for triadic-negative bone cancer( TNBC)
Two limelight bill conversations will partake results from the BEGONIA Phase Ib/ II trial testing Imfinzi( durvalumab) combinations in advanced or metastatic TNBC, showing the eventuality to drive bettered issues with the addition of ADCs.
Also, streamlined results from the TROPION- PanTumor01 Phase I trial of datopotamab deruxtecan monotherapy will show encouraging and durableanti-tumour exertion, and a manageable safety profile in heavilypre-treated cases with metastatic TNBC. The TROPION- Breast02 Phase III trial is assessing datopotamab deruxtecan as 1st- line remedy for cases with metastatic TNBC.
Source link: https://www.astrazeneca.com/
